STAT

Recursion’s incoming CEO: Beyond hype on AI-driven drug development, it’s time to show results

In a Q&A, Recursion’s incoming CEO acknowledges hype around the idea of using AI to expedite drug development, and says it's ...

Recursion’s Incoming CEO Needs To Prove That AI Drug Development Can Pay Off

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week.

Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?

Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at ...

Recursion’s Incoming CEO Needs To Prove That AI Drug Development Can Pay Off. Plus: Stop Hiding Your Wins

Welcome to this week’s ForbesWomen newsletter, which every Thursday brings news about the world’s top female entrepreneurs, ...

Is Recursion Pharmaceuticals a Meme Stock?

Is that the case? Let's look into it and decide whether the company is worth investing in.
Network World

What are TPUs? Your guide to tensor processing units and AI acceleration

This guide shows how TPUs crush performance bottlenecks, reduce training time, and offer immense scalability via Google Cloud ...

Is Recursion Pharmaceuticals Inc. (RXRX) One of the Best Mid Cap Stocks to Buy According to Hedge Funds?

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best mid cap stocks to buy according to hedge funds. On November 1 ...

Algorithm finds smallest dataset that guarantees optimal solutions to complex problems

Determining the least expensive path for a new subway line underneath a metropolis like New York City is a colossal planning challenge—involving thousands of potential routes through hundreds of city ...